Patents by Inventor Michael Asensio

Michael Asensio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-VISTA ANTIBODIES AND USES THEREOF
    Publication number: 20240132593
    Abstract: The present disclosure provides antibodies to V-domain Ig-containing Suppressor of T cell Activation (VISTA) and compositions comprising such antibodies. Also provided are methods of using antibodies that specifically binds to VISTA to treat diseases, e.g., to treat cancer.
    Type: Application
    Filed: February 18, 2022
    Publication date: April 25, 2024
    Inventors: Shawn P. Iadonato, Thierry Guillaudeux, Eric J. Tarcha, David Scott Johnson, Adam Shultz Adler, Rena Aviva Mizrahi, Yoong Wearn Lim, Michael Asensio
  • RECOMBINANT POLYCLONAL PROTEINS TARGETING COVID-19 AND METHODS OF USE THEREOF
    Publication number: 20230287112
    Abstract: Provided herein are compositions comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells and plasmablasts. Also provided are methods of using the RPPs.
    Type: Application
    Filed: April 4, 2023
    Publication date: September 14, 2023
    Inventors: David Scott Johnson, Sheila Keating, Adam Shultz Adler, Michael Asensio, Kacy Stadtmiller, Emily Benzie, Ariel Niedecken, Angelica V. Medina-Cucurella, Rena Aviva Mizrahi, Yoong Wearn Lim
  • ANTI-CTLA-4 BINDING PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20230265192
    Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to CTLA-4 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: July 2, 2021
    Publication date: August 24, 2023
    Applicant: GigaGen, Inc.
    Inventors: David Scott JOHNSON, Adam Shultz ADLER, Rena Aviva MIZRAHI, Yoong Wearn LIM, Michael ASENSIO, Erica Lyn STONE
  • RECOMBINANT POLYCLONAL PROTEINS TARGETING ZIKA AND METHODS OF USE THEREOF
    Publication number: 20230265171
    Abstract: Provided herein are compositions comprising recombinant polyclonal protein (RPP) derived from mammalian plasma cells and plasmablasts. Specifically, RPPs specific to Zika virus are provided. Also provided are the methods of using the RPP for treatment of viral infection and the methods of making the RPPs.
    Type: Application
    Filed: April 27, 2023
    Publication date: August 24, 2023
    Inventors: David Scott JOHNSON, Sheila KEATING, Adam Shultz ADLER, Michael ASENSIO, Kacy STADTMILLER, Emily BENZIE, Ariel NIEDECKEN, Angelica V. Medina-Cucurella, Rena Aviva MIZRAHI, Yoong Wearn LIM
  • Recombinant polyclonal proteins targeting Zika and methods of use thereof
    Patent number: 11718660
    Abstract: Provided herein are compositions comprising recombinant polyclonal protein (RPP) derived from mammalian plasma cells and plasmablasts. Specifically, RPPs specific to Zika virus are provided. Also provided are the methods of using the RPP for treatment of viral infection and the methods of making the RPPs.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: August 8, 2023
    Assignee: GigaGen, Inc.
    Inventors: David Scott Johnson, Sheila Keating, Adam Shultz Adler, Michael Asensio, Kacy Stadtmiller, Emily Benzie, Ariel Niedecken, Angelica V. Medina-Cucurella, Rena Aviva Mizrahi, Yoong Wearn Lim
  • Recombinant polyclonal proteins targeting COVID-19 and methods of use thereof
    Patent number: 11685779
    Abstract: Provided herein are compositions comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells and plasmablasts. Also provided are methods of using the RPPs.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: June 27, 2023
    Assignee: GigaGen, Inc.
    Inventors: David Scott Johnson, Sheila Keating, Adam Shultz Adler, Michael Asensio, Kacy Stadtmiller, Emily Benzie, Ariel Niedecken, Angelica V. Medina-Cucurella, Rena Aviva Mizrahi, Yoong Wearn Lim
  • Engineered Cells Expressing Anti-Viral T Cell Receptors and Methods of Use Thereof
    Publication number: 20230124951
    Abstract: Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell rectors with specificity against EBV or CMV peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mammalian cells as cell therapies against viral infections.
    Type: Application
    Filed: July 13, 2022
    Publication date: April 20, 2023
    Inventors: Matthew James Spindler, David Scott Johnson, Ayla Lynn Nelson, Ellen Kathleen Wagner, Adam Shultz Adler, Yoong Wearn Lim, Michael Asensio
  • Engineered cells expressing anti-viral T cell receptors and methods of use thereof
    Patent number: 11421220
    Abstract: Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell rectors with specificity against EBV or CMV peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mammalian cells as cell therapies against viral infections.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: August 23, 2022
    Assignee: GigaMune, Inc.
    Inventors: Matthew James Spindler, David Scott Johnson, Ayla Lynn Nelson, Ellen Kathleen Wagner, Adam Shultz Adler, Yoong Wearn Lim, Michael Asensio
  • Recombinant Polyclonal Proteins and Methods of Use Thereof
    Publication number: 20220243197
    Abstract: Provided herein are compositions comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells and plasmablasts. Also provided are methods of using the RPPs.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 4, 2022
    Inventors: David Scott Johnson, Adam Shultz Adler, Rena Aviva Mizrahi, Yoong Wearn Lim, Michael Asensio, Sheila Keating, Renee Leong, Jackson Leong
  • ENGINEERED CELLS EXPRESSING ANTI-TUMOR T CELL RECEPTORS AND METHODS OF USE THEREOF
    Publication number: 20220213167
    Abstract: Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell receptors with specificity against gp100 peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mammalian cells as cell therapies against melanoma tumors.
    Type: Application
    Filed: May 1, 2020
    Publication date: July 7, 2022
    Inventors: Matthew James Spindler, David Scott Johnson, Adam Shultz Adler, Michael Asensio
  • Anti-PD-1 Binding Proteins and Methods of Use Thereof
    Publication number: 20220064302
    Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 3, 2022
    Inventors: David Scott Johnson, Adam Shultz Adler, Rena Aviva Mizrahi, Yoong Wearn Lim, Michael Asensio
  • Anti-CTLA-4 Binding Proteins and Methods of Use Thereof
    Publication number: 20220064303
    Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to CTLA-4 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 3, 2022
    Inventors: David Scott Johnson, Adam Shultz Adler, Rena Aviva Mizrahi, Yoong Wearn Lim, Michael Asensio, Erica Lyn Stone
  • RECOMBINANT POLYCLONAL PROTEINS TARGETING ZIKA AND METHODS OF USE THEREOF
    Publication number: 20220064268
    Abstract: Provided herein are compositions comprising recombinant polyclonal protein (RPP) derived from mammalian plasma cells and plasmablasts. Specifically, RPPs specific to Zika virus are provided. Also provided are the methods of using the RPP for treatment of viral infection and the methods of making the RPPs.
    Type: Application
    Filed: September 8, 2021
    Publication date: March 3, 2022
    Inventors: David Scott Johnson, Sheila Keating, Adam Shultz Adler, Michael Asensio, Kacy Stadtmiller, Emily Benzie, Ariel Niedecken, Angelica V. Medina-Cucurella, Rena Aviva Mizrahi, Yoong Wearn Lim
  • Anti-PD-L1 Binding Proteins and Methods of Use Thereof
    Publication number: 20220056137
    Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to PD-L1 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: December 27, 2019
    Publication date: February 24, 2022
    Inventors: David Scott Johnson, Adam Shultz Adler, Rena Aviva Mizrahi, Yoong Wearn Lim, Michael Asensio
  • RECOMBINANT POLYCLONAL PROTEINS TARGETING COVID-19 AND METHODS OF USE THEREOF
    Publication number: 20220041715
    Abstract: Provided herein are compositions comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells and plasmablasts. Also provided are methods of using the RPPs.
    Type: Application
    Filed: July 27, 2021
    Publication date: February 10, 2022
    Inventors: David Scott Johnson, Sheila Keating, Adam Shultz Adler, Michael Asensio, Kacy Stadtmiller, Emily Benzie, Ariel Niedecken, Angelica V. Medina-Cucurella, Rena Aviva Mizrahi, Yoong Wearn Lim
  • Engineered Cells Expressing Anti-Viral T Cell Receptors and Methods of Use Thereof
    Publication number: 20220002710
    Abstract: Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell rectors with specificity against EBV or CMV peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mammalian cells as cell therapies against viral infections.
    Type: Application
    Filed: September 21, 2021
    Publication date: January 6, 2022
    Inventors: Matthew James Spindler, David Scott Johnson, Ayla Lynn Nelson, Ellen Kathleen Wagner, Adam Shultz Adler, Yoong Wearn Lim, Michael Asensio